The nitric oxide (NO) signalling pathway is altered in cardiovascular diseases, including
systemic and pulmonary hypertension, stroke, and atherosclerosis. The vasodilatory …

There have been significant recent advances in the understanding of the pathophysiology of
pulmonary hypertension, and a growing number of therapeutic agents have become …

Abstract Problem/Condition: Pulmonary hypertension, which is listed on hospital records
and death certificates as either primary (ie, idiopathic) pulmonary hypertension or pulmonary …

Pulmonary arterial hypertension (PAH) can be a rapidly progressive disorder and is
associated with high rate of mortality, despite medical intervention. With the availability of …

Background: Market authorization does not guarantee patient access to any given drug. This
is particularly true for costly orphan drugs because access depends primarily on co …

Background Pulmonary arterial hypertension (PAH) is a rare but fatal disease. Little is
known about the economic burden associated with PAH patients in the US. Objectives The …

Objective: To estimate direct medical costs and resource use for commercially-insured
patients within two pulmonary hypertension sub-groups: pulmonary arterial hypertension …

Purpose: To describe the benefits of a feasible, outpatient exercise training program on
exercise tolerance and health-related quality of life (HRQL) in individuals with pulmonary …

Pulmonary hypertension is a rare disorder caused by vasoconstriction of the pulmonary
arteries that leads to elevation of pulmonary vascular resistance, right ventricular failure, and …

Pulmonary arterial hypertension (PAH) is an uncommon condition associated with
significant morbidity and mortality. It has diverse aetiology with differing clinical …